Pharmaceutical - Pharmaceutical, Japan

Filter

Current filters:

PharmaceuticalJapan

Popular Filters

1 to 25 of 119 results

Takeda motesanib fails to meet primary endpoint in Ph III NSCLC study

Takeda motesanib fails to meet primary endpoint in Ph III NSCLC study

17-02-2015

In a second research negative this month, Japan’s largest drugmaker Takeda Pharmaceutical has today…

JapanmotesanibOncologyPharmaceuticalResearchTakeda Pharmaceutical

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

13-02-2015

German pharmaceuticals and chemicals major Merck KGaA is to end the co-promotion of Erbitux (cetuximab)…

Bristol-Myers SquibbErbituxJapanLicensingMerck & CoOncologyPharmaceutical

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

13-02-2015

Japanese drug major Eisai has published results of its SELECT Phase III study, showing its lenvatinib…

EisaiHealthJapanlenvatinibPharmaceuticalWeakness

AbbVie submits NDA to Japanese regulators for ombitasvir/ paritaprevir/ ritonavir combination in hepatitis C

AbbVie submits NDA to Japanese regulators for ombitasvir/ paritaprevir/ ritonavir combination in hepatitis C

12-02-2015

US drugmaker AbbVie has submitted a New Drug Application to the Japanese Ministry of Health, Labor and…

AbbVieJapanNephrology and Hepatologyombitasvir/paritaprevir/ritonavirPharmaceuticalRegulation

Novartis' Japan unit faces 15-day suspension over trial data manipulation

Novartis' Japan unit faces 15-day suspension over trial data manipulation

04-02-2015

The Japanese unit of Swiss drug major Novartis is facing suspension following allegations of data manipulation…

DiovanHematologyJapanLegalNovartis PharmaceuticalsOncologyPharmaceuticalRegulation

ALK's partner Torii submits NDA in Japan for house dust mite sublingual tablet

ALK's partner Torii submits NDA in Japan for house dust mite sublingual tablet

26-01-2015

Denmark-based allergy specialist ALK Abello’s Japanese partner, Torii Pharmaceutical, has submitted…

ALK AbelloImmunologicalsJapanPharmaceuticalRegulationSLIT-tabletTorii Pharma

Eric Terhaerdt appointed senior vice president of global development operations at Astellas

Eric Terhaerdt appointed senior vice president of global development operations at Astellas

15-01-2015

Japanese drug major Astellas Pharma has appointed Eric Terhaerdt as senior vice president of global development…

AstellasAstellas PharmaBoardroomEric TerhaerdtJapanPharmaceutical

Kyowa Hakko Kirin to commercialize Syndax’ entinostat in Japan and Korea

Kyowa Hakko Kirin to commercialize Syndax’ entinostat in Japan and Korea

08-01-2015

Shares of Japanese mid-size drugmaker Kyowa Hakko Kirin rose 3.55% to 1,138 yen by afternoon trading…

Asia-PacificentinostatJapanKyowa Hakko KirinLicensingOncologyPharmaceuticalSyndax Pharmaceuticals

Daiichi Sankyo gets Japanese approval for Methylene Blue

05-01-2015

Japanese drug major Daiichi Sankyo has received approval in Japan for the manufacture and marketing of…

Daiichi SankyoHematologyJapanMethylene Blue InjectionPharmaceuticalProvepharmRegulation

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

05-01-2015

Japanese drug major Eisai has announced a Phase III trial of antiepileptic drug Fycompa (perampanel)…

EisaiFycompaJapanNeurologicalperampanelPharmaceuticalResearch

Sumitomo Dainippon’s lurasidone meets primary endpoint in Ph III study

30-12-2014

Japanese drug major Sumitomo Dainippon Pharma has released positive preliminary findings from a Phase…

Dainippon Sumitomo PharmaJapanLatudalurasidoneNeurologicalPharmaceuticalRegulationResearch

Sumitomo Dainippon to halve its Japanese production sites

Sumitomo Dainippon to halve its Japanese production sites

29-12-2014

Japanese pharma company Sumitomo Dainippon is to reduce its four production sites in Japan to just two.

Dainippon Sumitomo PharmaJapanPharmaceuticalProductionSumitomo

Otsuka acquires Avanir for $3.5 billion

Otsuka acquires Avanir for $3.5 billion

02-12-2014

The US subsidiary of Japanese drug maker Otsuka has acquired US CNS specialist Avanir Pharmaceuticals…

AvanirJapanMergers & AcquisitionsNeurologicalNuedextaOtsuka PharmaceuticalPharmaceuticalUSA

Milestone for Skyepharma as Flutiform debuts in Spain; and as Abriff in Italy

Milestone for Skyepharma as Flutiform debuts in Spain; and as Abriff in Italy

01-12-2014

UK oral and inhalation drug specialist Skyepharma says that, following regulatory approval and agreement…

AbriffFinancialFlutiformItalyJapanKyorin PharmaceuticalMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharmaSpainZambon

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

28-11-2014

Japanese drug major Daiichi Sankyo and Belgian drugmaker UCB have entered into an agreement to jointly…

Daiichi SankyoJapanlacosamide Tablet and InjectionLicensingNeurologicalPharmaceuticalUCBVimpat

Asthma drug market set to grow $23 billion by 2023

28-11-2014

The asthma treatment market value will grow across eight major countries (the USA, UK, France, Germany,…

AdvairAstraZenecaAustraliaEuropeGlaxoSmithKlineJapanMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicortUSA

Japan’s Takeda optimizes global production network

27-11-2014

Takeda Pharmaceutical has decided to focus its Osaka plant (Osaka Prefecture, Japan) to become a specialty…

GermanyJapanLupronOncologyPharmaceuticalProductionTakeda Pharmaceutical

Merck & Co submits first regulatory filing for omarigliptin, in Japan

Merck & Co submits first regulatory filing for omarigliptin, in Japan

25-11-2014

US pharma giant Merck & Co has submitted a new drug application for omarigliptin, its investigational…

DiabetesJapanMerck & CoomarigliptinPharmaceuticalRegulation

Kissei files for Japanese approval of PA21 for hyperphosphatemia

21-11-2014

Japanese mid-sized drugmaker Kissei Pharmaceutical says that a new drug application for PA21 (development…

FreseniusJapanKissei PharmaceuticalNephrology and HepatologyPA21PharmaceuticalRegulationVelphoroVifor Pharma

Takeda joins forces with GE Healthcare on liver disease research

Takeda joins forces with GE Healthcare on liver disease research

13-11-2014

Japan’s largest drugmaker Takeda Pharmaceutical has entered into an alliance agreement with UK-based…

GE HealthcareJapanNephrology and HepatologyPharmaceuticalResearchTakeda Pharmaceutical

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

Qiagen signs agreement with Astellas Pharma to develop companion diagnostics

Qiagen signs agreement with Astellas Pharma to develop companion diagnostics

29-10-2014

Netherlands-based company Qiagen has announced a master collaboration agreement with Japanese drug major…

Astellas PharmaJapanLicensingNetherlandsOncologyPharmaceuticalQiagen

Eisai and Arena announce top line results of lorcaserin HCl with phentermine HCl

Eisai and Arena announce top line results of lorcaserin HCl with phentermine HCl

29-10-2014

Japanese drug major Eisai and Arena Pharmaceuticals have announced top-line results of a pilot study…

Arena PharmaceuticalsEisaiGastro-intestinalsJapanlorcaserinPharmaceuticalPhentermine HydrochlorideResearch

1 to 25 of 119 results

COMPANY SPOTLIGHT

Menarini

Back to top